MedTrace Logo

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

NCT05143190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-11-21

No results posted yet for this study

Summary

A sub-set of patients who participated in PTR-01-002 will be enrolled in an open-label study, if they meet the study eligibility criteria.

Conditions

Interventions

DRUG

PTR-01

Intravenous recombinant collagen 7

Sponsors & Collaborators

  • Phoenix Tissue Repair, a BridgeBio company

    collaborator UNKNOWN

  • Phoenix Tissue Repair, Inc.

    lead INDUSTRY

Principal Investigators

  • Dan Rudin, MD · Phoenix Tissue Repair

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2022-06-20
Completion
2022-08-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05143190 on ClinicalTrials.gov